What the trials adjudicated, and how
We give background rates alongside trial rates, because an event occurring during treatment is not thereby caused by it.
The archive
Page 143 of 170 of this archive, newest first.
What the anaesthetists said, and then said again
The evidence is real, modest, and mostly retrospective. The guidance is correspondingly cautious and has been revised toward individualisation.
Canada health authority warns on falsified semaglutide pens
Reported from the analysis, not from a warning notice.
TFC declines, for the 4th time, to name its synthesis house
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
Independent analysis puts a WWB survodutide lot at 99.2%, against 95.5% on the certificate
The supplier has not disputed the finding. It has not explained the gap either.
Halvard & Pike Apothecary of Portland, Maine enters a consent decree and stops sterile preparation
The observation that closes a facility is rarely the dramatic one.
The figure of merit this trade chose, and the four it did not
Chromatographic purity is cheap, fast and comparable-looking. Those three properties, and not its usefulness, explain why it became the industry’s single figure of merit.
One receptor, several signals: the case for reading retatrutide as a biased agonist
What the in-vitro data supports, what it does not, and where the extrapolation to a person begins.
From the floor in Qingdao: 19 posters, one theme
Reported from the sessions, and from the two hours afterwards.
What the new Poland guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
WXT declines, for the 23rd time, to name its synthesis house
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
What VendorInvestigate is able to certify about a sealed vial, and what it is not
The Journal has read several hundred certificates from twenty companies. We set out what the documents actually cover, and what a reader is filling in from imagination.
The dose that got you here and the dose that keeps you here
What the labels permit, what clinicians do, and the size of the gap between them.
The submitted sample: the weakest link in the whole system
The condition on arrival is recorded by some services and not others, and it is one of the more informative lines in a report.
The consolidator trading as Meridian Freight Partners enters a consent decree and stops sterile preparation
The observation that closes a facility is rarely the dramatic one.
A supplier suspends shipping to Portugal after 16 consecutive customs detentions
The route did not close because of a rule about peptides.
What an 11% rise in coupling-reagent prices does to a 10 mg vial
Follow the resin, not the catalogue.
Holograms, QR codes and other things that are not verification
Reported from the analysis, not from a warning notice.
Endotoxin is not a microorganism, and killing the bacteria does not remove it
Three compendial method families are in routine use and a fourth, based on a recombinant enzyme rather than crab lysate, is now compendial in its own right.
A shortage listing ends. 19 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
The slide that was not in the abstract
Reported from the sessions, and from the two hours afterwards.
Shenzhen export categories for peptide intermediates were quietly renamed
Follow the resin, not the catalogue.
Independent analysis puts a WXT semaglutide lot at 98.8%, against 95.3% on the certificate
The Journal submitted the sample and paid for the analysis. The vendor was told in advance.
The anatomy of the most reproduced page in this trade
Nothing on this page is difficult. It is simply unfamiliar, and unfamiliarity is what makes a weak certificate look like a strong one.
Why "muscle-sparing" is a marketing term and not a measurement
The rule that a quarter of weight lost is lean tissue has been in textbooks for decades and does not survive close reading.
Inspectors cite Calder Vale Peptides of Skipton over sterility assurance
The observation that closes a facility is rarely the dramatic one.
VendorInvestigate result on a Zhuhai dulaglutide lot lands 2.6 points below the supplier’s figure
A reminder that a purity figure is the output of a method, and that methods differ.
What changed at WWB in May, and what the company will not say about it
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
The lead-in, the randomisation, and the year that followed
The evidence on stopping is better than the evidence on almost anything else in this field, because somebody deliberately randomised it.
Escalating past the approved maximum, examined honestly
Where the curve flattens, what flattens with it, and what does not.